Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pfizer, Amgen , Clovis Oncology and more - PRE-MARKET

A look at what stocks are moving the needle, up and down, before the bell in New York
Pfizer, Amgen , Clovis Oncology and more - PRE-MARKET
Biotech stocks are in focus in pre-market in New York

It should be rather more of a busy day on Wall Street today after thin volumes on Monday due to the Columbus Day holiday.

Stocks to watch on the day include Pfizer (NYSE:PFE), which jumped up  1.13% to US$36.55 after hours.

It has emerged that the group is potentially considering the sale of its consumer health unit.

The business posted US$3.4bn in revenue last year, which was "distinct enough" from the core business that there could potential for it to be more valuable outside the company.

Well-known brands at the business include ChapStick.

Elsewhere, the biopharma firm Amgen Inc (NASDAQ:AMGN)  saw shares nudge 0.11% lower after hours to US$ 185.25  after the group said the key FDA  had accepted what's called a supplemental biologics license application for Prolia.

The drug is an antibody  to treat osteoporosis, treatment-induced bone loss, and giant cell tumor of bone, among others.

Elsewhere, Clovis Oncology Inc (NASDAQ:CLVS) saw shares add 1.80% to US$83.50 after the bell, after it revealed that it had submitted a supplemental new drug application to the FDA for anti cancer agent rucaparib.

Also in pre-market, Imperva Inc (NASDAQ:IMPV)  shares lost 2.53% on the day yesterday, and lost 1.69% after the bell to US$44.25 after it reported the resignation of its finance chief Terry Schmid.

Schmid named Aaron Kuan as the new person in the role on an interim basis effective November 16, 2017.

View full PFE profile View Profile

Pfizer Timeline

November 23 2015

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use